- Home
- USCB vs MRVI Comparison
USCB vs MRVI Comparison
Compare USCB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- MRVI
- Stock Information
- Founded
- USCB 2002
- MRVI 2014
- Country
- USCB United States
- MRVI United States
- Employees
- USCB N/A
- MRVI N/A
- Industry
- USCB Major Banks
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- MRVI Health Care
- Exchange
- USCB Nasdaq
- MRVI Nasdaq
- Market Cap
- USCB 316.4M
- MRVI 312.4M
- IPO Year
- USCB 2021
- MRVI 2020
- Fundamental
- Price
- USCB $17.00
- MRVI $2.67
- Analyst Decision
- USCB Buy
- MRVI Hold
- Analyst Count
- USCB 3
- MRVI 10
- Target Price
- USCB $20.50
- MRVI $6.84
- AVG Volume (30 Days)
- USCB 27.3K
- MRVI 1.9M
- Earning Date
- USCB 07-24-2025
- MRVI 08-06-2025
- Dividend Yield
- USCB 2.35%
- MRVI N/A
- EPS Growth
- USCB 78.48
- MRVI N/A
- EPS
- USCB 1.39
- MRVI N/A
- Revenue
- USCB $84,457,000.00
- MRVI $241,856,000.00
- Revenue This Year
- USCB $23.28
- MRVI N/A
- Revenue Next Year
- USCB $7.02
- MRVI $10.62
- P/E Ratio
- USCB $12.23
- MRVI N/A
- Revenue Growth
- USCB 34.16
- MRVI N/A
- 52 Week Low
- USCB $11.88
- MRVI $1.67
- 52 Week High
- USCB $21.86
- MRVI $10.03
- Technical
- Relative Strength Index (RSI)
- USCB 59.44
- MRVI 67.02
- Support Level
- USCB $16.08
- MRVI $2.32
- Resistance Level
- USCB $17.80
- MRVI $2.72
- Average True Range (ATR)
- USCB 0.48
- MRVI 0.15
- MACD
- USCB 0.13
- MRVI 0.05
- Stochastic Oscillator
- USCB 64.09
- MRVI 92.36
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.